Navigation Links
MannKind Corporation Reports Second Quarter Financial Results
Date:8/11/2008

- Conference Call Today at 5:00 p.m. EDT -

VALENCIA, Calif., Aug. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2008.

For the second quarter of 2008, total operating expenses were $80.9 million, compared to $75.4 million for the second quarter of 2007. This increase was primarily attributable to increased research and development (R&D) expenses which totaled $67.6 million for this quarter compared to $61.5 million for the same quarter in 2007. The increase in research and development expenses for the three months ended June 30, 2008 as compared to the same period in the prior year was primarily due to increases in manufacturing costs, clinical trial costs, and stock-based compensation expense. General and administrative (G&A) expenses decreased by $0.6 million to $13.3 million for the second quarter of 2008 compared to the second quarter of 2007. The decrease in general and administrative expenses for the three months ended June 30, 2008 as compared to the same period in the prior year was primarily due to lower professional service fees, partially offset by increases in stock-based compensation expense and salary related expenses.

For the first six months of 2008, operating expenses totaled $154.9 million, compared to $152.7 million in the first half of 2007. R&D expenses for the first six months were $126.0 million, compared to $125.3 million in 2007. The increase in R&D expenses for the first six months was primarily due to increases in stock-based compensation expense and manufacturing costs, partially offset by lower clinical trial costs. G&A expenses increased by $1.5 million to $28.9 million for the first half
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports First Quarter Financial Results
4. MannKind to Present at the Morgan Stanley Healthcare Conference
5. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. MannKind Corporation Response to Recent Market Events
8. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
9. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. MannKind to Present at the Wachovia 2008 Healthcare Conference
11. MannKind to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and Chief Executive Officer of Neurocrine Biosciences, will ... Miami.   The live presentation takes place ... The presentation will be webcast and may be accessed ... Listeners are encouraged to visit the website ...
(Date:3/3/2015)... Santa Clara, California (PRWEB) March 03, 2015 ... and development service company, has launched a new Life ... research reagents for preclinical research. , The first ... monoclonal antibody isotype controls, and soon to be released ... The company will continue to expand their life science ...
(Date:3/3/2015)... MA (PRWEB) March 03, 2015 HubCast® ... Supply Chain, today announced the expansion of its Global ... color-matched print to 850 the world’s largest cities across ... Chain extends to 137 countries providing global enterprises ease, ... print procurement process from online order to real-world delivery ...
(Date:3/3/2015)... , March 3, 2015 AtheroNova Inc. (OTCQB: ... Operations, Inc., filed voluntary petitions under Chapter 11 of the ... of California , Santa Ana ... The Company,s Chapter 11 cases are expected to be jointly ... a Bankruptcy Court supervised asset sale process, for all or ...
Breaking Biology Technology:Crown Bioscience Launches Life Science Product Catalog 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... The Board of,Directors, meeting today under the chairmanship of Albert Saporta, approved,STALLERGENES, half year consolidated financial statements:, (EUR millions) ... ... % ... change, Sales ...
... NLTX ), today announced that Peter Strumph, Chief ... the Biotech Industry,conference on Thursday, September 4, at 1:30 ... City. Mr. Strumph will provide a company,overview and update ... The presentation will be webcast live and can be ...
... Aug. 27 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... that Jerry McMahon, Ph.D., chairman and CEO,will participate ... he,will provide a corporate overview, including a discussion ... lead product candidate., -- The Thomas Weisel ...
Cached Biology Technology:Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 2Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 3Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2Poniard Pharmaceuticals Announces Upcoming Conference Participation 2
(Date:2/18/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that its ... investors to participate via webcast. , Cowen and Company ... March 3, 2015 at 11.20 a.m. Eastern Time , ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... for these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... of Rostock in Germany has developed a new way to ... using less energy than before. It,s expected that this breakthrough ... diverse range of applications; including transport and medical devices. ... open access journal Materials Today , reports on the ...
... research by UM bioclimatology Assistant Professor Ashley Ballantyne ... Arctic temperatures during the Pliocene era. His research ... the July issue of Nature Geoscience. The full ... Palaeoecology: An International Journal for the Geosciences ., ...
... sector, are accessible marine resources as they grow in ... every year and have become an important part of ... based on macroalgae for bioenergy, cosmetics and biomedicine. , ... led by the Spanish National Research Council (CSIC) that ...
Cached Biology News:Cool it, quick: Rapid cooling leads to stronger alloys 2Japan, China and South Korea account for 84 percent of the macroalgae patents 2
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Request Info...
Biology Products: